Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19 ARF as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF-Mdm2-p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14 ARF expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.
P
Ca is the second most frequently diagnosed cancer in men with 4200,000 new cases reported in the USA annually 1 . Screening for the sensitive yet diagnostically unspecific biomarker prostate-specific antigen (PSA) has led to a substantial rise in the diagnosis of early stage PCa 2 . The failure of current diagnostic tools to reliably distinguish non-aggressive tumours from aggressive ones to predict therapeutic response 3 urgently calls for the identification of better biomarkers to guide treatment. Furthermore, there is need for novel targeted therapies of metastatic PCa based on a better molecular understanding of the disease 4 . The lack of markers to stratify PCa cases into low-and high-risk groups results in overtreatment of 20-42% of patients 5 . STAT3, the major downstream mediator of IL-6 signalling, was shown to be related to advanced tumour growth, by tumour-autonomous mechanisms and by modulating tumour-associated stroma 6 . Although STAT3 activation is observed in B50% of PCa 7 its functional role in tumorigenesis and metastasis has not been elucidated. Data from the majority of human PCa cancer cell lines support an oncogenic and growth promoting role of IL-6 and STAT3 in vitro 8 . However, metastatic LNCaP cells were growth inhibited in vitro and in vivo in response to IL-6 treatment 8 . Moreover, treatment of patients with an IL-6 blocking antibody did not result in a survival advantage in patients with advanced PCa 9 . Thus, addressing the precise in vivo role of IL-6/STAT3 in PCa is of utmost importance to reassess diagnostic and therapeutic approaches.
PTEN is one of the most frequently deleted or mutated tumour suppressors in PCa, with an estimated incidence of 70% in metastatic PCa, causing aberrant activation of the PI3K-AKT-mTOR signalling pathway 10 . Loss of Pten leads to senescence, which is critically regulated by the ARF-p53 pathway 11 . While the tumour suppressor ARF (p14 ARF in humans; p19 ARF in mice) is readily degraded in normal cells, it is stabilized to increase p53 function on loss of Pten. ARF was shown to augment p53 stability by promoting the degradation of Mdm2, a negative regulator of p53. Concomitant inactivation of Pten and p53 leads to bypass of senescence and as a consequence to a malignant PCa phenotype 11 . Previous studies report PTEN-STAT3 signalling crosstalk in malignant glioblastoma 12 , but the detailed molecular mechanisms in cancer progression and metastasis remain unresolved.
In this study, we show that loss of IL-6/Stat3 signalling in a Pten-deficient PCa model accelerates cancer progression leading to metastasis. Loss of IL-6/Stat3 signalling in PCa bypasses senescence via disrupting the ARF-Mdm2-p53 tumour suppressor axis. We identify ARF as a novel direct Stat3 target. Notably, loss of STAT3 and p14 ARF expression correlates with increased risk of recurrence in PCa patients. In addition, STAT3 and p14 ARF expression was lost in metastasis compared with the primary tumours. We identified STAT3 and CDKN2A mutations in primary PCa patients. Furthermore, PCa metastases show a high frequency of STAT3 and CDKN2A deletions. We propose STAT3 and ARF as prognostic markers for high versus low risk PCa patient stratification.
Results
Co-deletion of Stat3 and Pten triggers PCa. To study the role of PTEN and STAT3 in PCa development, we took advantage of mice with conditional loss of Pten in the prostate epithelium (Pb-Cre4 Pten fl/fl ) hereafter referred to as Pten pc À / À (ref. 13 ). Stat3 protein levels were markedly induced in Pten pc À / À compared with wild-type (WT) prostate epithelium (Fig. 1a,b) . Pten pc À / À tumours showed strong Akt Ser473 phosphorylation and, unexpectedly, Stat3 Tyr705 and Ser727 phosphorylation suggesting maximal transcriptional activity of Stat3 (Fig. 1a,b and Supplementary Fig. 1a ). In addition, we observed an increase in IL-6Ra levels in tumour cells and soluble IL-6R serum levels ( Supplementary Fig. 1a-c) as well as increased Stat3, IL-6Ra and IL-6 mRNA levels ( Supplementary Fig. 1d ) in Pten pc À / À PCa compared with WT controls. To prove that loss of Stat3 signalling influences PCa formation, we generated mice with concomitant loss of Pten and Stat3 in prostate epithelial cells. Prostate-specific deletion of Pten and Stat3 was confirmed by PCR ( Supplementary Fig. 2a ). Immunohistochemistry (IHC) analysis confirmed loss of pY-Stat3 and Stat3 in Pten pc À / À Stat3 pc À / À tumour cells ( Supplementary Fig. 2b ), while still being present in stromal cells (Supplementary Fig. 2c) . Surprisingly, and in sharp contrast to the oncogenic role of Stat3 in many cancers 14, 15 , Pten pc À / À Stat3 pc À / À mice showed accelerated PCa formation with up to sixfold increase in tumour weight compared with Pten pc À / À tumours at different stages of PCa development (Fig. 1c,d and Supplementary Fig. 2d,e) . Pten pc À / À Stat3 pc À / À tumours showed increased numbers of Ki-67 positive (Ki-67 þ ) proliferating cells and reduced numbers of cleaved caspase 3 positive (CC3 þ ) apoptotic cells compared with Pten pc À / À prostates (Fig. 1e,f) .
Compared with Pten pc À / À mice 16 , Pten pc À / À Stat3 pc À / À mice displayed a significantly reduced median survival (Fig. 1g) . Intriguingly, Pten pc À / À Stat3 pc À / À mice developed high-grade (poorly differentiated) PCa with liver and lung metastases (Fig. 2a) . Histopathological analysis of PCa-bearing animals revealed widespread metastasis in 75% of Pten pc À / À Stat3 pc À / À mice. By contrast, Pten pc À / À mice only showed local invasion into seminal vesicles and never developed distant metastases ( Fig. 2b and Fig. 3a ). Our data demonstrate that Stat3 suppresses malignant progression of Pten-deficient PCa. We found reduced p53 protein expression in Pten pc þ / À Stat3 pc À / À prostates ( Supplementary Fig. 3b ). Pten heterozygosity alone had no effect on p53 expression as demonstrated before 11 . Interestingly, prostate-specific loss of Stat3 (Stat3 pc À / À ) led to development of PIN lesions in prostates at 19 weeks of age ( Supplementary Fig. 3c ). Analysis of consecutive sections revealed invasive regions and high-grade PIN in Pten pc À / À mice at 19 weeks of age, whereas Pten pc À / À Stat3 pc À / À mice showed early progression to poorly differentiated adenocarcinoma (Fig. 2c) . At 52 weeks of age Pten pc À / À Stat3 pc À / À tumours had developed into poorly differentiated carcinomas with 86% penetrance compared with Pten pc À / À tumours, which showed only signs of focal invasion and late adenocarcinoma formation (Fig. 2d) . Notably, Pten pc À / À tumour cells uniformly expressed nuclear Stat3 at 19 weeks of age (Fig. 2e) , whereas more advanced tumours at 52 weeks of age showed profoundly reduced nuclear Stat3 expression (Fig. 2e,f) , suggesting that Stat3 expression decreased during PCa progression.
To further dissect the tumour promoting effects of loss of Stat3, we established primary mouse Pten À / À PCa cells with stable, short hairpin RNA (shRNA) mediated knockdown of Stat3. Western blot and IHC analyses confirmed efficient Stat3 knockdown in these cells ( Fig. 3a and Supplementary Fig. 4a ). In line with our genetic data, Pten À / À mouse PCa cells with shStat3 knockdown were significantly more invasive in a transwell invasion assay compared with control cells (Fig. 3b) . We verified the aggressive behaviour of PTEN-STAT3 double deficient tumour cells in an organotypic, physiologically relevant in vitro three-dimensional cancer model 18 . Pten À / À -shStat3 PCa cells displayed a more invasive phenotype compared with control cells in organotypic assays (Fig. 3c and Supplementary  Fig. 4b ). In addition, Pten À / À -shStat3 cells showed increased anchorage-independent cell growth in soft agar compared with Pten À / À PCa cells expressing non-targeting shRNA (control shRNA) (Fig. 3d) . To corroborate our findings in human cells, combined knockdown of STAT3 and PTEN in human RWPE-1 prostate cells (Fig. 3e) increased invasiveness in organotypic assay compared with control and single knockdown cells (Fig. 3f,g ).
Notably, re-expression of STAT3 in human PC3 prostate carcinoma cells, which lack STAT3 expression ( Supplementary  Fig. 4c ), led to significantly decreased cell numbers and reduced foci formation ( Fig. 3h and Supplementary Fig. 4d ,e). These data are consistent with a cell-autonomous tumour suppressive role of Stat3 in PCa. Stat3 regulates the ARF-Mdm2-p53pathway. Since loss of Pten triggers senescence thereby restricting cancer progression and metastasis 11 , we next tested whether Stat3 exerts a tumour suppressive function by activating senescence-inducing programmes in Pten pc À / À PCa cells 19 at an early stage of PCa development (19 weeks) . Senescence is generally characterized by upregulation of p53, cyclin-dependent kinase inhibitor 1 (Cdkn1, p21), promyelocytic leukaemia protein (PML) and elevated senescence-associated-b-galactosidase activity 20 . Of note, Pten pc À / À Stat3 À / À tumours lacked p21 expression, displayed reduced numbers of PML nuclear bodies and decreased SA-b-Gal activity compared with Pten pc À / À tumours (Fig. 4a,b and Supplementary Fig. 5a,b) , suggesting Stat3 as a novel mediator of senescence in response to loss of Pten. Senescence associated with loss of Pten was shown to be bypassed by deletion of p53 leading to early lethality 11 . We show here that loss of Stat3 and Pten revealed a phenotype strikingly similar to that of p53 and Pten loss 11 . Intriguingly, Stat3 and Pten deletion resulted in downregulation of p53 expression in the prostate epithelium, which was accompanied by the loss of p19 ARF (Fig. 4a,b) . The p53 expression in the tumour stromal cells remained unchanged ( Supplementary  Fig. 5c ). Since p19 ARF is a critical regulator of Mdm2 degradation 21 , our results suggest that the tumour suppressive capacity of Stat3 in senescent tumour cells 22 may rely on the p19 ARF -Mdm2-p53 tumour suppressor axis. Recently, co-inactivation of p53 and ARF was linked to human triple-negative breast cancer progression through IFNb-STAT1-ISG15 signalling 23 . Interestingly, ISG15 and Stat3 protein expression levels paralleled each other in the PCa mouse models ( Supplementary Fig. 6a ). This suggests an altered ISGylation system, which could be independent of androgen receptor expression 24 ( Supplementary Fig. 6b ). It is noteworthy, that numerous AR-positive tumour cells were observed in the metastases of the Pten pc À / À Stat3 pc À / À PCa mouse models ( Supplementary Fig. 6c ), underlining the relevance of our model to human PCa 25 . Molecular pathological analysis confirmed AR-positive tumour nodules in five out of five cases of lung metastases consist of 66% AR-positive cells ( Supplementary Fig. 6d ).
Mechanistically, Pten was shown to block PI3K-mediated translocation of Mdm2 into the nucleus, where it promotes rapid degradation of p53 (ref. 26) . In line with the published function of PML to increase p53 stability by sequestering Mdm2 to the nucleolus, disruption of Pten and Stat3 resulted in increased Mdm2 protein levels (Fig. 4b) . Therefore, loss of Stat3 promotes PCa development by bypassing senescence regulated by the p19 ARF -p53 axis. We therefore hypothesize that Stat3 may act through ARF as an important gatekeeper controlling senescence counteracting metastasis, which we tested further.
Immunoblot and IHC analyses revealed a positive correlation between Stat3 and p19 ARF levels. Moreover, loss of Stat3 led to a profound decrease in p19 ARF protein (Fig. 4a,b) . Transcript levels of the well-established Stat3 target genes Socs3 and c-fos 27 
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Pten -/- Fig. 7a,b) . Stat3 pc À / À prostates displayed a significant decrease in p19 ARF protein and mRNA levels compared with WT controls (Fig. 4c,d) , suggesting direct regulation of p19 ARF expression by Stat3. We first tested this by analysing p19 ARF expression in passage-matched homozygous Stat3 knockout (Stat3 KO ) and WT mouse embryonic fibroblasts (MEFs). Both p19 ARF protein and mRNA levels were significantly reduced in the absence of Stat3 ( Supplementary Fig. 7c,d ). Consistently, MEFs expressing one or two hyperactive Stat3 alleles (Stat3 C/ þ and Stat3 C/C ) from the endogenous Stat3 locus 28 displayed upregulation of p19 ARF protein and mRNA (Fig. 4e,f) . In silico analysis of the p19 ARF promoter 29 predicted two potential Stat3-binding sites ( Supplementary  Fig. 7e ). Chromatin immunoprecipitation (ChIP) experiments showed approximately threefold increase in Stat3-binding activity to the proximal p19 ARF promoter region in WT compared with Stat3 pc À / À prostate tissue (Fig. 4g) . We next wanted to know if Stat3 binding was further elevated in Pten-deficient tumours since Pten loss increased ARF expression. By performing ChIP in Pten pc À / À primary mouse prostate tumours, we demonstrated a 15-fold increase of Stat3 binding to the p19 ARF promoter (Fig. 4h) , which was abrogated in Pten pc À / À Stat3 pc À / À tumours. These data identify p19 ARF as a novel Stat3 target gene.
Loss of IL-6 and Pten leads to cancer and metastasis. IL-6 signalling is the major regulator of Stat3 with therapeutic relevance.
To address whether Stat3 activation in Pten pc À / À mice depends on IL-6 signalling, we crossed Pten pc À / À mice with IL-6 À / À mice 30 .
Co-deletion of IL-6 and Pten triggered early lethality (Fig. 5a ), progressive high-grade adenocarcinoma formation with increased tumour growth and weight (Fig. 5b,c) , resulting in disseminated metastases (Fig. 5d) , for example, in the liver ( Supplementary  Fig. 8a ). Loss of IL-6 in Pten heterozygous prostate tissue also resulted in high-grade invasive PCa with metastasis formation at 15 months of age ( Supplementary Fig. 8b ). Like Pten pc À / À Stat3 pc À / À mice, Pten pc À / À IL-6 À / À mice showed markedly enhanced PCa growth ( Supplementary Fig. 8c,d ) at 19 weeks of age, increased Ki-67 þ but decreased CC3 þ expression levels compared with Pten pc À / À prostates ( Fig. 5e-g ). IHC analysis revealed absence of pY-Stat3 and Stat3 expression in Pten pc À / À IL-6 À / À tumours ( Supplementary Fig. 8e ). Intriguingly, in vivo blocking of IL-6/STAT3 signalling by the JAK1/2 inhibitor ruxolitinib in human LNCaP xenografts showed significantly enhanced tumour size and weight (Fig. 6a,b) . The ruxolitinib-treated xenografts also had markedly increased numbers of Ki-67 þ cancer cells accompanied by a decrease in STAT3 and p14 ARF expression (Fig. 6c) . Moreover, ruxolitinib treatment of LNCaP cells significantly promoted colony formation (Fig. 6d) . Of note, LNCaP cells lack JAK1 expression and do not respond to interferon signalling 31 . Moreover, STAT3 was shown to be activated in xenografts of LNCaP cells, most likely due to the sole action of JAK2 (refs 32,33) . Ruxolitinib is a dualspecific JAK1/2 kinase inhibitor and therefore, effects of ruxolitinib on the LNCaP xenograft model are likely to be a consequence of JAK2/STAT3 inhibition independent of IFN gamma signalling.
Loss of STAT3 and ARF in PCa is associated with metastases. The fact that activated STAT3 induces its own transcription 34 led us to measure IL-6 and STAT3 mRNA levels in primary human tumours and to correlate them with clinical outcome. Using the Taylor gene expression profiling data set (GSE21032) 35 , we dichotomized samples based on the z-scores of IL-6 or STAT3 expression. Specifically for IL-6 expression, samples that had zscoreso À 2 were defined as low IL-6 and all others (zscores4 À 2) were used as a comparator for prognostic significance. Conversely, samples that had STAT3 z-scores42 were defined as STAT3 high and all other samples (z-scoreso2) were used as comparators. Time to biochemical recurrence (BCR) was assessed as an indicator of individual prognosis. BCR was defined by an increase to 40.2 ng ml À 1 PSA in serum. Of note, patients with low IL-6 expression levels showed a significantly higher risk of BCR compared with patients with high IL-6 expression (Fig. 7a) . In line, patients with high Stat3 mRNA levels demonstrate good prognosis. This may reflect a higher level of senescence competence compared with patients with lower Stat3 mRNA levels (Fig. 7b) .
We next tested whether expression of STAT3 and p14 ARF can serve as novel prognostic markers predicting the risk of BCR and metastatic disease progression. STAT3 and p14 ARF levels were independently evaluated by five pathologists in 204 human PCa specimens from patients who underwent radical prostatectomy. Patient samples were categorized into low or high expression groups based on staining intensities and number of positive cells (Methods) using validated antibodies ( Supplementary Fig. 9a,b) . Classification was verified by quantitative histopathological image analysis 36 (Supplementary Fig. 10a ). Indeed, increased Gleason score (GSC) correlated with low STAT3 or p14 ARF protein expression levels. In addition, we found a strong direct correlation between STAT3 and p14 ARF in accordance with p14 ARF being a direct target of STAT3 (Fig. 7c,d ). STAT3 expression was significantly decreased in PCa (GCSr7) compared with PIN areas of 67 matched patient samples ( Supplementary Fig. 10b,c) . Strikingly, both low STAT3 expression (Po0.007; log-rank test) and low p14 ARF (Po0.000001; log-rank test) expression were associated with poor outcome (Fig. 7e,f) . Moreover, combined loss of p14 ARF and STAT3 expression in tumours of PCa patients predicted the worst outcome (P ¼ 0.000007, log-rank test) (Fig. 7g) . Using multivariate analysis, we identified p14 ARF as a reliable, independent prognostic marker for PCa, which has a twofold higher hazard ratio compared with GSC (Fig. 7h) . In accordance with the literature 25,37 , we found increased AR expression in metastases compared with primary human PCa ( Supplementary Fig. 11a,b) . IHC analysis of matched primary and metastatic human PCa revealed significant loss of PTEN expression in metastatic PCa (Fig. 8a and Supplementary  Fig. 11c ), suggesting an important role of PTEN loss in PCa metastasis. PTEN levels showed no significant correlation with STAT3 or p14 ARF protein expression in a cohort of 4200 patients ( Supplementary Fig. 11d,e) . Moreover, we demonstrated that loss of STAT3 and/or p14 ARF is associated with progression to metastatic disease (Fig. 8b-d ). This is supported by expression data from matched primary and metastatic PCa samples ( Supplementary Fig. 12a-c) , where in all seven cases a significant loss of STAT3 and p14 ARF expression occurred in the metastases.
Current data suggest that PCa harbour common genomic and epigenomic alterations 38, 39 . We analysed large-scale human cancer data sets (International Cancer Genome Consortium (ICGC) and COSMIC databases) and the GEO methylation database 40 . Surprisingly, we found mutations of STAT3 (2.5%) and CDKN2A (2.3%) in a cohort of 529 patients with primary PCa (Fig. 8e) . We found five missense-, one nonsense-and several conservative STAT3 mutations in primary PCa patients ( Supplementary  Fig. 13a ). STAT3 and/or CDKN2A were frequently deleted in metastatic PCa (Fig. 8f and Supplementary Fig. 13b ), which have been confirmed in an independent data set 35 (Fig. 8g) . Notably, in 66% of STAT3 deletions, PTEN was co-deleted in both metastases data sets investigated (Fig. 8f,g ). However, we neither detected human IL-6 mutations nor methylation of STAT3 and CDKN2A loci in primary and metastatic PCa (Supplementary Figs 13c,d and Supplementary Figs 14a,b) .
Discussion
Due to the lack of prognostic markers for risk stratification, many PCa patients suffer from overtreatment and a severely reduced quality-of-life. Understanding the molecular genetics underlying PCa and the identification of genetic and/or biochemical markers predicting clinical outcome is therefore of high priority.
Our data reveal robust upregulation of the IL-6/Stat3 signalling axis in a PCa mouse model as well as in patient specimens. Loss of Stat3 or IL-6 accelerates the progression to metastatic PCa; this stands in sharp contrast to the proposed oncogenic function of IL-6/Stat3 signalling in PCa 33, 41, 42 . Moreover, there are contradictory studies on the role of senescence in tumorigenesis [42] [43] [44] . Whether these different findings are due to the use of distinct mouse models, strains and species remains to be addressed. Here we combine an array of experimental approaches including in vivo models, mechanistic data with comprehensive human pathological, molecular and genetic data to underscore the tumour suppressive role of STAT3 (ref. 45 ). Thereby we identify STAT3 and its transcriptional target ARF as novel powerful prognostic markers for PCa patients. In PCa and several other cancers, elevated serum IL-6 levels correlate with a poor prognostic outcome for patients 46 . This sparked the development of IL-6 inhibitors to abrogate hyperactive IL-6/ STAT3 signalling. However, blocking IL-6/STAT3 signalling was ineffective in patients with advanced PCa 9,47 , challenging this oncogenic concept. We show that loss of Stat3 accelerates malignant progression of prostate tumours through abrogation of p19 ARF expression, which we identified as a novel direct Stat3 target gene. Several reports have demonstrated that loss of Pten leads to increased senescence associated with p53 stabilization triggered by p19 ARF (refs 11,48) . Inactivation of Stat3 and Pten revealed striking similarities to the malignant phenotype observed after deletion of Pten and p53 (ref. 11). Our model implicates high Stat3 and/or IL-6 levels in senescence-competent PCa and therefore does not contradict the general observation of high IL-6 and/or Stat3 expression in many cancers. We show that impaired p19 ARF expression in Stat3-deficient PCa is accompanied by loss of senescence. In line with our data, concomitant loss of Pten and p19 ARF in MEFs resulted in bypass of senescence, induction of hyperproliferation and oncogenic transformation 11 . Accordingly, overexpression of p19 ARF leads to p53-dependent cell growth arrest and induces senescence 49 . However, systemic p19 ARF deficiency in Pten pc À / À mice did not accelerate PCa or enhance p53 accumulation 50 , which might be explained by inflammatory cytokines and/or growth factors produced by the multiple tumours developing in other organs 51 . Here we identified an unpredicted tumour suppressor role for Stat3 signalling in PCa by its ability to control the tumour suppressor ARF-Mdm2-p53 pathway in a context-dependent manner. Therefore, we propose the STAT3-ARF axis as a previously unknown safeguard mechanism against malignant progression in PCa. Importantly we also demonstrate that loss or inhibition of STAT3-ARF signalling enables tumour progression and metastasis formation. This is reflected in patients with PCa, since loss of STAT3 and/or p14 ARF expression significantly correlates with poor prognosis in large independent data sets. Therefore, our study identifies STAT3 and ARF as potential novel prognostic markers predicting BCRfree survival. The importance of the STAT3-ARF axis is corroborated by the presence of STAT3 mutations in primary PCa and frequent deletions of STAT3 and ARF in metastatic PCa. The significant loss of STAT3 and p14 ARF expression from matched primary and metastatic PCa samples underlines the relevance of our findings.
Interestingly, loss of PTEN expression in primary human PCa did not correlate with overall survival 52 and could not predict PCa-specific death 53 . Moreover, heterozygous PTEN deletions far outnumber homozygous deletions in primary human PCa 54 and we show here that PTEN is mutated or lost only in a small subset (4.7%) of a large cohort of patients with primary PCa. However, PTEN is lost in 450% of human PCa metastases 55, 35 , suggesting an important role for PTEN in this process. Finally, we show in our study that STAT3 is co-deleted with PTEN in 66% of human PCa metastases in two independent data sets. Since PTEN is mutated or lost in only a minor fraction of primary PCa, other aberrations must occur (oncogene induction or loss of tumour suppressor function) to activate STAT3 and ARF to induce senescence in human cancers. Indeed, several studies indicate that different aberrations can lead to induction of senescence in human cancers 48, 56 .
Many human PCa cases are diagnosed with low GSCs, which are of clinical low risk. Only a minority of these tumours will progress to aggressive lethal PCa. We show that ARF is an independent prognostic marker with a twofold higher hazard ratio compared with GSC (Fig. 7h ). This will enable significantly improved stratification of low risk PCa patients into active surveillance, avoiding severe side effects such as incontinence and/or impotence. Together with a previously defined four-gene We have uncovered a paradigm shift in understanding the key function of STAT3 in tumorigenicity and metastatic progression in PCa. Therefore, our results call for cautious use of anti-IL-6-STAT3 signalling blockers in the treatment of PCa as this may turn low-grade tumours into highly malignant cancers by loss of senescence controlled by the STAT3-ARF axis. As IL-6/STAT3 signalling blockers are successful in the treatment of chronic inflammatory or autoimmune diseases, their influence on PCa development needs to be carefully evaluated in future studies. Reactivating the IL-6/STAT3/ARF-dependent senescence pathway 57 might be a promising strategy for PCa therapy via downregulation of Mdm2 (ref. 58) or p53 induction 59 . Alternatively, triggering ARF-p53-independent cellular senescence by a small molecule inhibitor 60 , could be beneficial for PCa patients in whom other therapies have failed.
Methods
Generation of transgenic mice. Pten loxP/loxP mice crossed with male PB-Cre4 transgenic mice were generated as described previously 13, 61 . To generate prostatespecific deletion of Pten and IL-6, we took advantage of IL-6 À / À mice 30 . In a similar strategy, mice carrying Stat3 loxP/loxP 62 were maintained and crossed with PB-Cre4 Pten loxP/loxP transgenic mice. All mice were maintained on a C57BL/6 and Sv/129 mixed genetic background. Animal experiments were reviewed and approved by the Austrian ministry authorities and conducted according to relevant regulatory standards (BMWF-66.009/0281-I/3b/2012).
Immunohistochemistry and histological analysis. Immunohistochemistry and haematoxilin/eosin staining was performed with formalin-fixed paraffin-embedded (FFPE) tissue using standard protocols using consecutive sections. The following antibodies were used for immunohistochemistry: pY-Stat3 #9860). We used PTEN 63 and AR (1:250; DAKO, AR441) 64 antibodies validated for FFPE IHC. The STAT3 antibody was validated using SW620 colon cancer xenografts with shRNA-mediated knockdown ( Supplementary Fig. 9b ). The specificity of p14 ARF antibody was validated using the human melanoma cell lines 65 VM-28 (WT for p14 ARF ) and VM-7 (deletion at the p14 ARF locus).
All images were taken with a Zeiss AxioImager Z1, and quantification was performed with HistoQuest (TissueGnostics GmbH, Vienna, Austria, www.tissuegnostics.com) as described in detail in (ref. 36) . In brief, haematoxylin staining was used for cell identification. The range of intensities of the master marker (haematoxylin) and the immunohistochemical stainings were set by 
CDKN2A (21%)
Patient no. and CDKN2A in an independent data set of 37 metastatic PCa samples 35 .
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8736 ARTICLE autodetection of the software. All images were analysed with the identical settings after adjustments. The results are visualized in dot plot scattergrams and/or histograms. Cut-offs (to differentiate between positive and negative cells) and gates (to accentuate between cell populations) were set in the dot blots. For statistical analysis, the raw data were imported into GraphPad Prism 6 (GraphPad Software), analysed for significance and processed for data output. All images were taken with the same exposure time, signal amplification and objectives.
Western blot analysis. For protein expression analysis by western blot, frozen tissue samples and cell lysates were prepared as described 16 . Blots were blocked with 5% BSA or 5% non-fat dry milk in 1 Â TBS/0.1% Tween-20 for 1 h and incubated with the primary antibody overnight at 4°C. Primary antibodies were reactive to pY-Stat3 (1:500 dilution), pS-Stat3 (1:1,000 dilution), Stat3 (1:1,000 dilution; Cell Signaling, #9132), p19 ARF (1:1,000 dilution), p53 (1:1,000 dilution; Cell Signaling, #2524), p21 (1:500 dilution), b-actin (1:5,000 dilution; SigmaAldrich, A5316), p-Akt (1:1,000 dilution), Akt (1:2,000 dilution ), AR Statistical analyses. Data were analysed using GraphPad Prism 6 software. For comparing two groups unpaired Students t-test and for comparing more than two groups Tukeýs post hoc test was used. Fisher's exact test was employed when differences in distributions within groups were monitored. For Kaplan-Meier analysis and log-rank statistical evaluation of time to BCR, as well as evaluation of prognostic power in univariate and multivariate analysis, we used the IBM SPSS version 22 programme. To analyse Affymetrix SNP Chip 6.0 primary data, we used the AGCCytoScan Software together with the Chromosome Analysis Suite 3.0 (both Affymetrix), and deletions 4200 kb were considered significant. For analysis of mutations in primary PCa, we used the ICGC (www.icgc.org).
ELISA. For the detection of soluble sIL-6R in sera of mice, the samples were diluted 1:15 in 1% BSA-PBS. The ELISA was performed as described 67 . In brief, microtiter plates (Greiner Microlon) were coated with anti-murine IL-6-R pAB AF1830 (0.8 mg ml À 1 ; R&D Systems) in PBS. After blocking, 100 ml aliquots of cell lysates or culture supernatants were added. IL-6R bound to the plate was detected by biotinylated goat anti-mouse IL-6-R pAB BAF1830 (working concentration, 0.2 mg ml À 1 ; R&D Systems) followed by streptavidin-horseradish peroxidase (R&D Systems). The enzymatic reaction was performed with soluble peroxidase substrate (BM blue POD from Roche) at 37°C and the absorbance was read at 450 nm on a SLT Rainbow plate reader (Tecan). For the detection of murine IL-6 in sera of mice, the samples were diluted 1:3 with 1% BSA-PBS.
